BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial...

BioLineRx與Ayrmid簽署了Motixafortide（在美國以Aphexda出售）的許可協議，BioLineRx將獲得1000萬美元的預付款，並有資格獲得高達8700萬美元的額外商業潛在收入...

Benzinga · 11/21 19:33

BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda

Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous Transplantation In Patients With Multiple Myeloma.
BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23%.
BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC.
BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion.
Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases –

Aphexda是BioLineRx獲得FDA批准的幹細胞動員劑，適用於與Filgrastim聯合進行多發性骨髓瘤患者的採集及隨後自體移植。
BioLineRx將從Ayrmid Ltd.（gamida cell的母公司）獲得1000萬美元的預付款，以及最多8700萬美元的商業里程碑款項，並從淨銷售中獲得18%到23%不等的特許權使用費。
BioLineRx保留在實體腫瘤（包括胰腺導管腺癌）中開發和商業化Motixafortide的權利。
BioLineRx獲得了來自Highbridge Capital Management, LLC管理的某些所有基金類型的900萬美元股權投資，以支持公司的產品線和擴展。
這些交易使BioLineRx的運營費用和債務大幅減少，並允許公司專注於在腫瘤學和罕見疾病中有高度未滿足需求的領域進行開發活動。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。